---
title: "double_hit_and_double_expressors_in_lymphoma"
slug: "doublehitanddoubleexpressorsinlymphoma"
date: "2024-05-06"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ªï¼š[[non-Hodgkin lymphoma (NHL)]]

# double_hit_and_double_expressors_in_lymphoma

> Riedell PA, Smith SM. Double hit and double expressors in lymphoma: Definition and treatment. Cancer. 124(24):4622-4632. doi:10.1002/cncr.31646

- [[myc.md|MYC]]
- [[bcl2.md|BCL2]]
- [[bcl6.md|BCL6]]

![Figure: height:450px](https://i.imgur.com/DvcgJ7h.png)

---

![Figure: height:450px](https://i.imgur.com/s3ovecI.jpeg)

## Treatment for high grade B-cell lymmphoma

- [[robust.md|ROBUST]] : A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
- [[phoenix.md|Phoenix]]: Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma: çœ‹èµ·ä¾†æ˜¯ OS å¥½åƒæ²’ä»€éº¼å·®ğŸ˜‚
- [[polarix.md|POLARIX]]: çœ‹èµ·ä¾†æ˜¯ OS å¥½åƒæ²’ä»€éº¼å·®ğŸ˜‚
- [[l-mind.md|L-MIND]]: Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
  - single-arm, objective response: 34 (43%; 32â€“54) had a complete response and 14 (18%; 10â€“28) had a partial response
